Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

NCT05709171 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

GEP-NET
Neuroendocrine Tumors
Neuroendocrine Carcinoma
Neuroendocrine Carcinoma Metastatic

Interventions

DRUG: 18F-FDG
DRUG: 64Cu-Dotatate

Sponsor

Rigshospitalet, Denmark